arexvy rsv - Search News

News

GSK, RSV and European Medicines Agency

GSK applies to EU regulator for expanded use of RSV vaccine

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the age of 50 who are at risk of the disease, the British drugmaker said on Friday.

Medical Dialogues · 22h

GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older

· 2d

GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

Pharmabiz1d

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

STAT3d

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

pharmaphorum2d

Moderna's RSV shot gets US nod for use in younger adults

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results